【4月29日,中国生物制药核心企业北京泰德制药自主研发的妥洛特罗贴剂已实现全渠道供应】作为国产首款妥洛特罗贴剂,北京泰德以创新治疗方案借助互联网重塑慢性呼吸系统疾病治疗格局。全球透皮给药市场在老龄化加剧与慢性病负担加重的双重驱动下,正以5%的年复合增长率扩容。我国慢性呼吸系统疾病患者较多,传统呼吸疾病治疗有技术瓶颈,北京泰德制药的妥洛特罗贴剂采用缓释技术避免了这些瓶颈,提升药物利用率,降低哮喘患者...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.